Prime Medicine Inc

PRME

Company Profile

  • Business description

    Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

  • Contact

    60 First Street
    CambridgeMA02141
    USA

    T: +1 617 465-0013

    https://www.primemedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    146

Stocks News & Analysis

stocks

Strong guidance from undervalued ASX share

Shares surged after the announcement of first half fiscal 2026 guidance.
stocks

TSMC earnings: Refining guidance and expansion plans amid strong AI demand

We maintain our fair value estimate for TSMC stock.
stocks

Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio

Trying to make sense of a share caught up in irrational exuberance.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.7033.000.36%
CAC 408,287.7425.040.30%
DAX 4024,235.1480.670.33%
Dow JONES (US)48,578.72115.000.24%
FTSE 10010,574.4915.50-0.15%
HKSE26,160.33233.93-0.89%
NASDAQ24,102.7086.690.36%
Nikkei 22558,475.901,042.44-1.75%
NZX 50 Index12,905.67160.39-1.23%
S&P 5007,041.2818.330.26%
S&P/ASX 2008,946.9036.800.41%
SSE Composite Index4,051.434.12-0.10%

Market Movers